NKG2A+ inhibition that was achieved with certain anti-viral drugs later helped to restore cytotoxic lymphocyte counts and prevent T cell function exhaustion in COVID-19, indicating certain therapeutic benefits. The gene discussed is KLRC1; the disease is COVID-19.